Mytos co-founders Ali Afshar (L) and co-founder Ignacio Willats

Cell man­u­fac­tur­ing com­pa­ny rais­es $19M Se­ries A to in­crease ca­pac­i­ty, staff num­bers 

A Lon­don-based start­up that builds ma­chines that con­vert stem cells in­to more spe­cif­ic cell types has closed a $19 mil­lion Se­ries A round to boost its pro­duc­tion ca­pac­i­ty and in­crease its team of 30 staff mem­bers to 50.

My­tos is cur­rent­ly “at the lim­it” of how fast it can build its ma­chines, CEO Ali Af­shar told End­points News in an in­ter­view. And the Se­ries A is de­signed to in­crease the build and dis­tri­b­u­tion of its cell pro­duc­tion sys­tem — sim­ply named the My­tos Plat­form — and grow its sales and de­vel­op­ment work­force.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.